NasdaqGS:ERASBiotechs
Erasca (ERAS) Is Up 8.8% After ERAS-0015 Data And KRAS Patent Win Has The Bull Case Changed?
Erasca recently reported progress across its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for lead candidate ERAS-0015 in KRAS G12X lung and pancreatic cancers, along with accelerated clinical development and new collaborations.
The company also advanced its pan-KRAS inhibitor ERAS-4001, supported by a fresh US composition of matter patent that extends potential protection until 2043 and reinforces its position in targeted cancer...